Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
Information source: LG Life Sciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Intervention: Sancuso patch (Drug); Kytril inj.+Kytril tab. (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: LG Life Sciences Official(s) and/or principal investigator(s): Jin Seok Ahn, MD, PhD, Principal Investigator, Affiliation: Samsung Medical Center Tae Won Kim, MD, PhD, Principal Investigator, Affiliation: Asan Medical Center Dong Bok Shin, MD, PhD, Principal Investigator, Affiliation: Gachon University Gil Medical Center
Overall contact: Yun-Ae Eom, BS, Phone: 82-2-6924-3157, Email: yaeom@lgls.com
Summary
Multicenter, randomized, open-label, paralled-group, active-controlled study. The study is
to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS)
compared with the intravenous and oral Granisetron in the prevention of CINV associated with
moderately emetogenic Chemotherapy.
Patients scheduled to receive the one cycle of a ME chemotherapy regimen administered for
1-4 days will attend a Screening Visit 2 to 28 days before start of ME chemotherapy.
Eligible patients will be randomized to 1 of 2 treatment groups at the Randomization Visit
(1 to 2 days prior to ME chemotherapy).
- Sancuso patch
- Kytril inj.+Kytril tab.
The patch will be applied 2days (48-24h) prior to first daily dose of the moderately
emetogenic chemotherapy regimen and remain in place for 6 days. The patient will be assessed
daily until 4days after first chemotherapy administration. Adverse Events (AEs) will be
collected until 14 days after the final dose of IP. Non-serious AEs will be followed-up
until 14 days after the final dose of IP. Serious adverse events will be followed-up until
they are resolved, stable or until the patient is lost to follow-up.
Clinical Details
Official title: Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: The percentage of patients achieving Complete Response (CR) without rescue therapy from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
Secondary outcome: The percentage of patients achieving Complete Response (CR)The percentage of patients achieving Complete Control (CC) without rescue therapy from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen The percentage of patients achieving Complete Control (CC) severity of nausea severity of vomiting Frequency of nausea from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen Frequency of vomiting from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen Patient's satisfaction with anti-emetic therapy (Changes from Baseline to Day 5) The percentage of patients achieving Complete Response (CR) The percentage of patients achieving Complete Control (CC) severity of nausea severity of vomiting
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Male or female aged over 20 yrs
2. Histologically and/or cytologically proven cancer patients
3. Eastern Cooperative Oncology Group performance status 0, 1, 2
4. A cycle of moderately emetogenic chemotherapy(NCCN Guidelines)
5. Life expectancy of ≥ 3 months
6. Normal liver function and renal function(total bilirubin ≤ 1. 5 ULN, AST/ALT ≤ 2. 5
ULN, in case of liver metastases AST/ALT ≤ 5 ULN, serum creatinine ≤ 1. 5 ULN)
patients
7. Patients who signed the informed consent form
Exclusion Criteria:
A. Previous History
1. Hypersensitivity to adhesive plasters
2. Contraindications to 5-HT3 receptor antagonists
3. Any other relevant medical history (at the discretion of the investigator)
B. Concomitant Medical Condition
1. Current alcohol, drug or medication abuse
2. Currently pregnant or breast feeding women, including planning pregnancy
3. Clinically relevant abnormal laboratory values (at the discretion of the
investigator)
4. Clinically relevant heart, hepatic, renal, infectious, neurological or psychiatric
disorders, or any other major systemic illness (at the discretion of the
investigator)
5. Any cause for nausea and vomiting other than CINV
6. Any episode of retching, vomiting or uncontrolled nausea in the 72 h period prior to
the chemotherapy administration
7. Clinically relevant abnormal ECG parameters (at the discretion of the investigator)
C. Concomitant Therapy/Medication
1. Concomitant radiotherapy of total body, brain or upper abdomen within one week prior
to the study entry or planned during the study
2. Intake of medication to control the symptoms of a brain tumor, brain metastasis or
seizure disorder or neuropathy (unless peripheral neuropathy at the discretion of the
investigator)
3. Patients using selective serotonin reuptake inhibitor (SSRI) antidepressants (unless
a stable dose for the duration of the study)
4. Receipt of a narcotic analgesics (acceptable at the discretion of the investigator)
5. Receipt of any other clinical trial drug < 30 days before the study or during the
study
6. Scheduled to receive a neurokinin NK1 receptor antagonist, dopamine receptor
antagonist or another 5-HT3 receptor antagonist at 72 h prior to the administration
of the chemotherapy or scheduled to do those medication during chemotherapy duration
7. Drugs known to increase the QTc interval (unless a stable dose for the duration of
the study at the discretion of the investigator)
D. Other
1. Patients unlikely to comply with the study protocol (at the discretion of the
investigator), e. g. uncooperative attitude, inability to return for follow-up visits
and unlikelihood of completing the study
2. The patch adhesion level was not more than 50% on the day of chemotherapy or the
patch was not attached within two days before the chemotherapy
Locations and Contacts
Yun-Ae Eom, BS, Phone: 82-2-6924-3157, Email: yaeom@lgls.com
Samsung Medical Center, Seoul, Korea, Republic of; Recruiting Jin Seok Ahn, MD, PhD, Phone: 82-2-3410-3453, Email: ajis@skku.edu Jin Seok Ahn, MD, PhD, Principal Investigator
Additional Information
Starting date: February 2012
Last updated: August 15, 2012
|